Byonyks
Ahmed Muzmmal is a seasoned technology leader with extensive experience in founding and directing innovative companies in the medical devices, generative AI, and technology sectors. As a Cofounder and Director at Byonyks since November 2017 and previously serving as Director of Engineering at Gaper.io, Ahmed has demonstrated expertise in managing remote engineering teams. The entrepreneurial journey began with Mezino Technologies, where Ahmed served as Founder and CEO, focusing on IoT, Big Data, and cloud solutions. Other notable roles include Chief Technology Officer at The Main Tab, Technology Advisor at Royal Tag, and Director of Product Development at EveryRole. Additionally, Ahmed has contributed to academia as a Visiting Faculty Member at the University of Central Punjab and has a Bachelor of Science in Computer Science from the National University of Computer and Emerging Sciences.
This person is not in any teams
This person is not in any offices
Byonyks
Byonyks has pioneered the world’s first affordable Bloodless Dialysis machine, transforming care for kidney failure patients. Globally, over eight million people with kidney disease lack dialysis access—a costly, invasive, and time-consuming treatment that filters blood when kidneys fail. Many of these individuals face life-threatening consequences due to the lack of proper care. Byonyks addresses this critical issue with its Bloodless Dialysis machine; a safe, effective, portable, and non-invasive solution that’s more affordable than existing options. Our technology empowers patients to perform dialysis at home, overnight, while they sleep, allowing them to maintain their daily work and family responsibilities. The needle-free approach also reduces the risk of chronic infections such as HIV and Hepatitis C. Headquartered in the USA and South Asia, Byonyks is a medical device startup founded by Harvard/MIT graduates and industry experts. Our core team’s expertise contributes to over half of the operational peritoneal dialysis machines worldwide. The groundbreaking Bloodless Dialysis machine has saved multiple lives in South Asia and is currently under FDA review—a pivotal step towards making accessible kidney care a global reality.